Haemorrhagic shock induced by subcutaneous insulin injection
Sir-A number of chronic kidney disease patients with diabetes receive intensive insulin therapy nowadays, and many of them are also treated for several comorbidities. The combination of insulin therapy and other comorbidities could result in an unexpected complication.
Case
A 61-year-old female with type 2 diabetes and rheumatoid arthritis was admitted to our hospital on February 2009 for the curettage of a knee prosthesis infection. Intensive insulin therapy with 32-gauge tip × 6 mm needles was initiated 3 years previously. She was administered warfarin 1.5 mg for atrial fibrillation, and prothrombin time-international normalized ratio was prolonged to 2.0. Other laboratory tests revealed decreased kidney function (serum creatinine, 124 μmol/L; estimated glomerular filtration rate, 26.3 mL/ min/1.73 m 2 ) and normal platelet count (220 × 10 9 /L).
One day during her hospital stay, she injected her regular insulin by herself under the surveillance of a nurse in the left lower quadrant of the abdominal wall. Thirty minutes later, a subcutaneous haematoma appeared around the injection site. The haematoma enlarged rapidly despite the strenuous manual pressure performed immediately, and she subsequently developed haemorrhagic shock. Computer tomography detected a massive subcutaneous haematoma (Figure 1 ). Massive transfusion of 12 units of red blood cells and 12 units of fresh frozen plasma, along with further compression of the abdominal wall, was performed, and her haemodynamics stabilized. Follow-up abdominal angiography, however, did not detect the bleeding artery.
Discussion
Subcutaneous haematoma caused by insulin injection is a very rare complication [1-3]. One report described that inappropriate maneuver of insulin injection triggered haemorrhagic shock [2]. Although our case had several risk factors, such as chronic kidney disease, diabetes, rheumatoid arthritis, post-operative state and usage of warfarin, insulin injection was used properly. The fact that haemorrhagic shock occurred in this case is a warning of possible complications of insulin injection in high-risk patients.
Although fine needles are remarkably thin, therefore considerably reducing the risk of haemorrhage [4], lethal subcutaneous haematoma could happen even in a careful clinical setting. Renal thrombotic microangiopathy induced by β-interferon
Sir,
We read with interest the recent case report 'Minimal change disease with interferon-β therapy for relapsing remitting multiple sclerosis' [1] . In this paper, the authors include renal thrombotic microangiopathy (TMA) among rare side effects of interferon (IFN) therapy, more frequently described with IFN-α [2]. We report here our experience about this topic.
A 36-year-old white female with a 3-year history of multiple sclerosis and normal blood pressure and renal function was admitted for acute renal failure and pulmonary oedema. Three months previously, she started subcutaneous IFN-β-1a treatment of 22 μg thrice weekly. On admission, physical examination showed high blood pressure and severe pleuropericarditis without neurological or dermatological findings. Laboratory tests revealed microangiopathic haemolytic anaemia. Other immunological and microbiological laboratory tests were unremarkable. A renal biopsy disclosed signs of TMA; among 43 glomeruli, light microscopy revealed focal ischaemic signs and mild mesangial cell proliferation; vessel narrowing with thrombi and thickening of arteriolar walls and intimal onion skinlike swelling; light interstitial lymphomonocytic infiltration and focal tubular atrophy. Immunofluorescence showed mesangial IgM, C1q and fibrinogen staining. A diagnosis of haemolytic-uraemic syndrome was made. She was treated with transfusions, haemodialysis, plasma exchange and methylprednisolone i.v. followed by oral prednisone. Her cardiac function improved, and haematological signs progressively disappeared, but renal function did not recover. IFN-β treatment was discontinued. She is now receiving peritoneal dialysis treatment. IFN-α is known to cause a variety of renal lesions, including TMA [3, 4] , but to our knowledge, our observation is the first report of TMA induced by INF-β.
Editorial note: This letter had been sent to Aravindan A. et al., but we did not receive a response.
